Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament formula for treating female vaginal relaxation syndrome

A technology for vaginal relaxation and syndrome, which is applied in pharmaceutical formulas, medical preparations containing active ingredients, diseases, etc., to achieve the effects of no side effects, enhanced contractile function, and relieve symptoms

Pending Publication Date: 2021-02-12
湖南科诺康美生命科技有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a medicament formula for treating women's vaginal relaxation syndrome, which solves the problem of lacking a better medicament for treating women's vaginal relaxation in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] A pharmaceutical formulation for treating female vaginal relaxation syndrome, comprising mesenchymal stem cells and fillers, the volume ratio of mesenchymal stem cells to fillers is 1:1~1:3, and the mesenchymal stem cells are maternal umbilical cord placenta Or endometrium, the stem cell resuspension is physiological saline containing exosomes, and the filler is either or both of hyaluronate or collagen;

[0023] Wherein the preparation of exosomes comprises the following steps:

[0024] 1. The mesenchymal stem cells were cultured to the third generation, and when the cell growth density reached about 75%, the cells were washed three times with PBS, the culture medium was removed, and 25ml of normal saline / T175 was added, starved for 24 hours, and the supernatant was collected;

[0025] 2. Remove cells: centrifuge at 300g, 4°C for 10 minutes, and collect the supernatant;

[0026] 3. Remove dead cells: centrifuge at 2000g, 4°C for 10 minutes, and collect the supernatant...

Embodiment 2

[0037] A medicament formula for treating female vaginal relaxation syndrome, the medicament is injected, and the number of mesenchymal stem cells contained in a single injection dose is 1×10 6 Individual / kg, the injection of medicament comprises the following steps:

[0038] The first step is to fill the medicine into the injection needle;

[0039] In the second step, inject the needle from the anterior vaginal wall mucosa at a distance of 1.5cm from the vaginal opening. Push in 0.5-1ml of the injection preparation at four points on the upper, lower, left and right sides of the radius, and push back while pushing until a semicircumference is formed around the posterior wall of the middle section of the urethra;

[0040] The third step is to inject 2ml of medicine into the vagina after the injection is completed;

[0041] In this example, the injection method is simple and easy, and the injection preparation forms a semicircle around the posterior wall of the middle urethra. ...

Embodiment 3

[0043] A pharmaceutical formulation for the treatment of female vaginal relaxation syndrome includes mesenchymal stem cells and fillers; the volume ratio of mesenchymal stem cells to fillers is 1:1; the mesenchymal stem cells are derived from umbilical cord placenta donated by healthy puerperas (24 hours after birth), prepare, expand and culture on a GMP-compliant cell preparation platform until the 3rd-5th passage is frozen and stored for later use, and the quality inspection is qualified; the filler is mainly sodium hyaluronate and collagen, and it is prepared with normal saline. 1% concentration for standby;

[0044] According to the patient's weight, take 1*10 umbilical cord mesenchymal stem cells 6 / kg for resuscitation, washed with normal saline, resuspended cells with 5ml of exosomes prepared in Example 1, took normal saline to prepare 5ml of medical grade sodium hyaluronate suspension with a concentration of 1%, and mixed the two to prepare the medicament;

[0045]Inj...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicament formula for treating female vaginal relaxation syndrome. The medicament formula comprises mesenchymal stem cells and a filling agent, wherein the volume ratio of the mesenchymal stem cells to the filling agent is 1: 1-1: 3, the mesenchymal stem cells are parturient umbilical cord placenta or endometrium, the stem cell resuspension is normal saline containing exosome, and the filling agent is sodium alginate; the filling agent is any one or two of hyaluronate or collagen. In the formula of the medicament, the mesenchymal stem cells and the filler jointly play a role in filling in a short time, the symptom of female vaginal relaxation syndrome is relieved, the mesenchymal stem cells stimulate local tissue repair and angiogenesis in a microenvironment by secreting growth factors and cytokines at the same time, the contraction function of urethral sphincter is enhanced, and the effect of treating female vaginal relaxation syndrome is achieved; when thefiller and the allogeneic mesenchymal stem cells are gradually decomposed and absorbed by an organism, the newly-generated tissue achieves a purpose of relieving the female vaginal relaxation syndromefor a long time, so a problem of the female vaginal relaxation syndrome is better solved.

Description

technical field [0001] The invention relates to a medicament formula for treating female vaginal relaxation syndrome. Background technique [0002] Vaginal relaxation syndrome (VLS) is a common and frequently-occurring disease in gynecology, and it may be an early symptom of female pelvic floor dysfunction (PDP). VLS can lead to decreased sexual satisfaction and / or sexual dysfunction in women, and is often associated with diseases such as stress urinary incontinence and female reproductive tract inflammation, seriously affecting women's physical and mental health, but its etiology and pathogenesis have not yet been elucidated. In recent years, the disease has attracted more and more attention. Current studies have found that pregnancy, vaginal delivery, long-term increased intra-abdominal pressure, decreased estrogen levels, chronic obstructive pulmonary disease, constipation, obesity, long-term weight bearing, abnormal anatomical structure, physiological aging, iatrogenic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/28A61K31/728A61K38/39A61P15/02
CPCA61K35/28A61K31/728A61K38/39A61K9/0034A61P15/02A61K2300/00
Inventor 吴金芸雷登黄春兰
Owner 湖南科诺康美生命科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com